Home
overview
The SMi Group's 3rd Annual Depression & Anxiety Conference will bring together the key industry leaders to discuss the current and future opportunities within psychopharmacotherapy. 

This is a must-attend event for all those involved in addressing the growing challenges of diagnosing and treating the spectrum of distinct disorders.

This two day intensive forum will help you learn more about:
  • Drug development and new compounds: examine the emerging developments from the psychopharmaceutical drug pipelines and investigate the challenges that must be considered by the psychopharmacological community
  • Avoiding trial failure and improving study design: discover novel approaches specific to designing clinical studies for patients with mood disorders
  • Psychogenomics: hear about how genetics could provide the key to producing a truly individualised therapy system, and how the latest discoveries could help salvage previously doomed drug candidates
  • Translational issues in mood disorders: using translational methods to overcome traditional obstacles while developing new treatments for mood disorders
  • New targets and Biomarkers in lead discovery: identify new targets and improve biomarker selections to predict the effectiveness and safety of drugs for the treatment of depression

The conference features an excellent opportunity to hear from an international panel of experts, including:

  • Dr Lee E. Schechter, Therapeutic Area Head, Director Depression & Anxiety Research, Neuroscience Discovery, Wyeth
  • Dr Tanya Ramey, Clinical Lead, Neurosciences, Pfizer
  • Dr Pim Drinkenburg, Research Fellow, Head Biomonitoring Centre of Expertise Europe, Johnson & Johnson
  • Dr Zhengming Chen, Senior Director, Chemistry, DOV Pharmaceuticals
  • Dr Vincent F. Simmon, President & CEO, Xytis Pharmaceuticals
  • Dr Dinah Weissman, CEO, Biocortech
  • Dr Miguel Medina, Drug Discovery Director, Neuropharma
  • Dr Jill Rasmussen, Director, Psynapse
  • Prof Tonmoy Sharma, Director, Clinical Neuroscience Research Centre
  • Dr Andrew Harkin, Director, Neuropsychopharmacology Research, Trinity College Institute if Neuroscience, Trinity College, Dublin
  • Professor Charles Marsden, Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham Medical School

Who should attend Depression & Anxiety 2007?
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:

  • Behavioural Neuroscience
  • CNS
  • Biomonitoring
  • Clinical Development
  • Scientific Services
  • Research & Development
  • Psychopharmacology Research
  • Clinical Psychology
  • Clinical Pharmacodynamics
  • Marketing
  • Portfolio Management
  • Marketing
  • Project management

    Conference programme

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Amir Kalali

    Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California

    9:10 NOVEL APPROACHES TO TREAT DEPRESSION

    Lee E Schechter

    Lee E Schechter, Therapeutic Area Head, Director Depression & Anxiety Research, Neuroscience Discovery, Wyeth

  • Disease overview
  • Drug development and research
  • Challenges & strategies
  • Novel approaches as targets to treat the disease
  • 9:50 EFFICIENT CLINICAL DEVELOPMENT OF ANTIDEPRESSANTS AND ANTIANXIETY AGENTS

    Dr Tanya Ramey

    Dr Tanya Ramey, Clinical Lead, Neurosciences, Pfizer Global R&D

  • Unmet needs in depression and anxiety arena
  • Targets and animal models
  • Translational issues
  • Early signal of efficacy issues
  • Novel study design approaches
  • 10:30 Morning Coffee

    11:00 STRATEGIES FOR THE DESIGN AND SYNTHESIS OF NEW TREATMENTS FOR DEPRESSION AND ANXIETY

    Dr Zhengming (Jimmy) Chen

    Dr Zhengming (Jimmy) Chen, Senior Director of Chemistry, DOV Pharmaceuticals

  • Drugs that interfere with the reuptake and/or metabolism of biogenic amines have been used to treat depression for more than 4 decades
  • An important recent development has been the emergence of the triple uptake inhibitors (SNDRIs), which inhibit the reuptake of all three neurotransmitters most closely linked to depression: serotonin, norepinephrine, and dopamine
  • Preclinical studies and clinical trials indicate that a drug inhibiting the reuptake of all three of these neurotransmitters may produce greater efficacy than traditional antidepressants (SSRIs, etc.)
  • Design and synthesis of antidepressants based on the monoamine hypothesis of depression
  • Current approaches on design and synthesis of GABAA receptor modulators as potential treatment for anxiety disorders
  • 11:40 NOVEL NON-SEDATING ANXIOLYTICS – XY1029 AND XY2412

    Dr Vincent F Simmon

    Dr Vincent F Simmon, President & CEO, Xytis Pharmaceuticals

  • GABA A receptor targets
  • Beta 2,3 selective drugs - electrophysiology
  • Racemic generic drug with anxiolytic acitivity
  • Animal models
  • Development path
  • 12:20 Networking Lunch

    13:50 DECREASING THE PLACEBO RESPONSE IN ANTIDEPRESSANT CLINICAL TRIALS

    Tonmoy Sharma

    Tonmoy Sharma, Director, Clinical Neuroscience Research centre

    14:30 MRNA EDITING: NEW TARGET IN PSYCHIATRIC DISORDERS

    Dinah Weissmann

    Dinah Weissmann, CEO, Biocortech

  • What is mRNA editing?
  • Editing: a key target
  • ·Biocortech EDIT technology
  • Editing as a signature
  • Therapeutics and diagnostics perspectives
  • 15:10 Afternoon Tea

    15:30 LIGHT THERAPY AND SLEEP DEPRIVATION FOR DEPRESSION

    Professor Anna Wirz-Justice

    Professor Anna Wirz-Justice, Professor of Psychiatry, UNIVERSITY OF BASEL

    16:10 GLYCOGEN SYNTHASE KINASE-3 ß

    Dr Miguel Medina

    Dr Miguel Medina, Director, Drug Discovery, Neuropharma

  • Lithium salts as medication
  • Lithium molecular targets
  • GSK-3 mediating signalling
  • GSK3 and mood disorders
  • GSK3 inhibitors
  • 16:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Amir Kalali

    Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California

    9:10 NEW COLLABORATIVE OUTCOME MEASURES IN EVALUATING DEPRESSION IN CLINICAL TRIALS

    Dr Amir Kalali

    Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California

  • Learn about new methodologies in developing outcome measures in depression
  • Review data generated by this approach
  • Discuss implications for other disorders
  • 9:50 IMPROVING CLINICAL TRIAL DESIGN

    Dr Jill Rasmussen

    Dr Jill Rasmussen, Director, Psi-napse

  • Novel clinical development strategies
  • Risk management Plans and post registration considerations- what should be addressed for depression and anxiety?
  • Paediatric investigation plans
  • 10:30 Morning Coffee

    10:50 PANEL DISCUSSION - THE LACK OF NOVEL TREATMENTS APPROVED FOR THE TREATMENT OF DEPRESSION

    Dr Amir Kalali

    Dr Amir Kalali, Vice President, Medical & Scientific Services,Global Scientific Head CNS, Quintiles & Professor of Psychiatry, University of California

    Lee E Schechter

    Lee E Schechter, Therapeutic Area Head, Director Depression & Anxiety Research, Neuroscience Discovery, Wyeth

    Dr Andrew Harkin

    Dr Andrew Harkin, Director of Neuropsychopharmacology Research, Trinity College Dublin

    Dr Charles Marsden

    Dr Charles Marsden, Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham Medical School

    11:50 TOPIC TBC

    Dr Geoffrey Burnstock

    Dr Geoffrey Burnstock, President, Autonomic Neuroscience Centre, Department of Anatomy and Developmental Biology, Royal Free and University College Medical School

    12:30 Networking Lunch

    13:30 BIOMARKER IDENTIFICATION VIA MONITORING TECHNOLOGIES

    Pim Drinkenburg

    Pim Drinkenburg, Head, CNS Center of Expertise - Biomonitoring , Johnson & Johnson

    14:10 IMPROVING THE LINK BETWEEN CLINICAL AND PRE-CLINICAL DATA

    Dr Irina  Antonijevic

    Dr Irina Antonijevic, Director, Translational Research, Lundbeck, Inc.

    15:10 IMPROVING TRANSLATIONAL MEDICINE AND ANIMAL MODELS

    Dr Andrew Harkin

    Dr Andrew Harkin, Director of Neuropsychopharmacology Research, Trinity College Dublin

    15:50 NOVEL APPROACHES TO THE INVESTIGATION OF DRUG ACTION IN ANIMAL MODELS OF MENTAL DISORDERS

    Dr Charles Marsden

    Dr Charles Marsden, Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham Medical School

  • Improving the translational value of information obtained using animal models of mental disorders
  • Adopting methodologies that are common to both animal and human studies
  • fMRI can be used in both and make it possible to identify the brain regions involved in drug action
  • New information about the neural pathways involved in drug action
  • 16:30 Chairman’s Closing Remarks and End of Conference

    +

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City


    Title

    SubTitle
    speaker image

    Content

    Title


    Description

    Download

    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71


    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.